119 results about "Antibody antigen" patented technology

A protein interface prediction method based on three-track coding comprises the following steps: combining a fine-tuned protein language model SiteT5 with evolutionary, geometric and statistical features extracted from a sequence, sending the combined features into a three-track coding network, and integrating a cyclic gating module, a multi-resolution aggregation module and a long sequence deformation module to obtain a protein interface prediction model SiteT5; the method comprises the following steps: respectively capturing a time sequence relation, a local mode and long-range dependence among residues, respectively mapping the three codes into different weights, carrying out point multiplication on the three codes, and carrying out aggregation through a multi-view cross attention module; then the protein residues are sent to a three-layer hierarchical interactive learning module, local structure and global dependency are cooperatively mined through an eight-head gating self-attention module and a position-by-position feedforward module, and finally the probability that each protein residue is an interface is obtained through a classifier. According to the invention, a protein-DNA interface, a protein-RNA interface, a protein-protein interface and an antibody-antigen interface can be effectively captured. And the robustness is ensured, and meanwhile, relatively high prediction precision is also shown.

Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.

Provided are an activity-regulatable IL-12 fusion protein and the use thereof. The fusion protein comprises a first structural unit, a second structural unit, and a third structural unit. The first structural unit is selected from a first Fc fragment, or a first antibody or an antigen-binding fragment thereof, wherein the first antibody or the antigen-binding fragment thereof has the binding activity to a tumor antigen or an immune checkpoint; the second structural unit is selected from a cleavable linker or a non-cleavable linker; and the third structural unit comprises an IL-12 cytokine or a functional fragment thereof. The second structural unit mediates the steric hindrance of the first structural unit to mask the activity of the IL-12 cytokine in the third structural unit, thereby reducing the toxic side effects of in-vivo use of the IL-12 cytokine. Compared with a wild-type IL-12, the fusion protein has the advantage of high safety, and can be further fused with an antibody Fab, scFv or VHH, an antigen-binding peptide or a recombinant protein, a polypeptide, etc. to obtain a multifunctional fusion protein that can be conditionally released and activated.

The application discloses a kind of vibration device for immunofluorescence method, belong to medical detection device field, the device adopts cavity, vibration unit, cooling device and sound insulation cotton, sound insulation cotton is used to reduce noise in experimental process, cooling device reduces the heat generated due to vibration, avoid the heat generated by vibration to cause the influence to sample;After energization, vibration unit forms a kind of vibration source, the vibration of slide in incubation box in cavity is driven by vibration, and then promote the exposure of fixed antigen / antibody epitope on slide, accelerate and antibody / antigen in incubation sample are combined, shorten incubation time, improve experimental efficiency.

This disclosure provides methods and apparatus for generating training data, training machine learning models, and analyzing biological samples. Generating training data includes: acquiring a first image of a biological sample; generating a first set of annotations for the first image based on a second image of the biological sample stained by a quantitative method that converts antibody / antigen complexes into dots; and outputting the first image and a benchmark truth including the first set of annotations as data for training a first machine learning model (“ML”) to analyze the biological sample. Furthermore, the generated (output) training data can then be used to train the ML model, and the trained ML model can be used to analyze the biological sample.

The invention relates to the technical field of medical adsorbents for blood perfusion, and discloses an application of a trans-cyclooctene group adsorbent based on a biological orthogonal reaction in preparation of a circulating tumor cell clearing preparation. The adsorbent adopts sephadex microspheres as a carrier, the surface of the carrier is modified with a trans-cyclooctene (TCO) group, a tetrazine (Tz) group is taken in by CTCs through modified mannose, the Tz group is expressed on the surface of a CTCs cell membrane in the form of glycoprotein through a Roseman-Warden pathway in cells, TCO and Tz are subjected to a biological orthogonal reaction specifically, and the adsorption capacity of the adsorbent is improved. The sephadex microsphere adsorbent can effectively enrich and remove CTCs in blood of the whole body of a patient through adsorption, and compared with a conventional single-antibody or multi-antibody capture technology, the sephadex microsphere adsorbent does not depend on antibody-antigen binding, and the capture efficiency of the CTCs can be remarkably improved through a biological orthogonal reaction.

The invention discloses an up-conversion nano-composite with a core-shell structure, a preparation method and application, and belongs to the technical field of biomedical bimodal nano-probes. According to the nanocomposite, up-conversion nanoparticles (UCNPs) serve as a core, metal-organic frameworks (MOFs) serve as a shell layer, horse radish peroxidase (HRP) is loaded on the shell layer, and UCNP (at) MOF / HRP is formed. Subsequent biological functional modification, such as coupling of an antibody, an antigen, nucleic acid and other substances, can be carried by an activating group or a metal coordination bond carried by a shell ligand of the upconversion nanocomposite MOF with the core-shell structure, so that the functions of specific recognition, targeted capture, specific loading and the like are realized.

The present disclosure addresses the problem of providing a therapeutic agent for a disease in which formation of tertiary lymphoid tissue occurs in a lesion.　This prophylactic or therapeutic agent for a disease in which formation of tertiary lymphoid tissue occurs in a lesion contains an anti-CD153 antibody having cytotoxicity or an antigen-binding fragment of the antibody.

Methods for using antibodies, antigen-binding antibody fragments, immunoconjugates and pharmaceutical compositions for the treatment of adenoid cystic carcinoma, and pharmaceutical compositions containing immunoconjugates.

Embodiments described herein relate to systems and methods for mapping molecules into interfaces. An example interface includes a visual interface having a map visualization. Example molecules include proteins, or any protein-like molecules or fragments thereof such as antibodies, antigens, proteins, lectins, receptors. Embodiments described herein relate to systems and methods for mapping molecules into interfaces by processing data using dimensionality reduction to generation representations of molecule maps (e.g. map visualizations).

This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and / or ADC) to a CSPG4 polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and / or ADCs) that bind to a CSPG4 polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer are provided.

Provided herein are antibodies, antigen-binding portions thereof, and antibody peptide conjugates that specifically bind to neuropilin-1 (NRP1) and various compositions of such antibodies, antigen-binding portions, and antibody-peptide conjugates. The disclosure also provides nucleic acids encoding the antibodies, antigen-binding portions thereof, or antibody peptide conjugates; cells comprising the nucleic acids; and methods for producing the antibodies, antigen-binding portions thereof, or antibody peptide conjugates. Also provided are methods for using the antibodies or antigen-binding portions thereof in therapeutics and diagnostics for cancer.

The invention relates to the technical field of biology, in particular to an SERS probe for Mfn2 detection, a preparation method of the SERS probe, an SERS sensor and application of the SERS sensor. Based on a surface enhanced Raman spectroscopy (SERS) technology, a gold nanoparticle SERS probe coated with an antibody 1 and a silver nanoparticle SERS probe coated with an antibody 2 are constructed, a sandwich structure is formed through combination of the antibody 1, an antigen and the antibody 2, the structure effectively improves SERS hot spot distribution and Mfn2 detection sensitivity, and traditional measurement steps are simplified. The constructed biologically coded SERS probe can be used for measuring Mfn2 with different concentrations. Based on the prepared SERS sensor, the dynamic measurement of the expression of the single living cell Mfn2 in the process of electrical stimulation of dental pulp stem cell odontogenic differentiation is realized, and the SERS sensor has wide clinical application prospect and transformation value in the aspects of measurement of protein molecules in a single cell organelle and diagnosis of Mfn2 related diseases.

The present invention relates to antigen binding molecules that specifically bind cellular bound fibroblast activation protein (cFAP). The antigen biding molecules significantly discriminate between cFAP and one or more soluble variants of fibroblast activation protein (FAP), including the one or more soluble variants of FAP known to be present in body fluids such as blood, plasma and serum. The antigen binding molecules comprise one or more antibodies and / or one or more antibody antigen binding domains or fragments, and, in particular, include one or more camelid single antigen binding domains, i.e. one or more VHH sequences. The present invention further relates to nucleic acid molecules encoding the antigen binding molecules or a component domain thereof, as well as vectors comprising said nucleic acid molecules. The invention also relates to a host cell comprising the vector(s) of the invention, as well as to methods for the production of an antigen binding molecule of the invention comprising culturing the host cell of the invention under suitable conditions and isolating the antigen binding molecule produced. Furthermore, the present invention relates to an antigen biding molecule obtainable by the method of the invention, to a composition comprising at least one of an antigen binding molecule of the invention, the nucleic acid molecule of the invention, the vector of the invention, the host cell of the invention or the antigen binding molecule produced by the method of the invention. The present invention also relates to the use of an antigen binding molecule of the invention for detecting and targeting cFAP in vivo or in vitro, in particular selectively over one or more soluble variants of FAP, for use as a therapeutic in the treatment of diseases characterized by cFAP or as a diagnostic agent.

Predictive models are deployed to generate epitope predictions (e.g., B-cell epitopes). Predictive models analyze structural features of a protein, such as an antibody, or an antibody-antigen pair, and can identify epitopes and paratopes.

The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection in a subject. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a sarbecovirus and / or SARS-CoV-2 infection.

The subject invention provides a composition comprising an enomomer which comprises a) a carrier molecule, and b) at least one aptamer, wherein the carrier molecule is an antibody, an antigen-binding moiety, a serum protein, an intracellular protein, a messenger RNA (mRNA) or human serum albumin.

The invention discloses a method for quantitatively detecting the content of PreScision protease by using a double-antibody sandwich. The method comprises the following steps: S1, coating an elisa plate with a capture antibody; s2, adding a sample to be detected into the coated elisa plate; s3, incubating by taking the HRP binding antibody as an enzyme-labeled antibody, developing by using a TMB developing solution, and detecting an OD value by using a microplate reader with the wavelength of 450 nm; and S4, drawing a standard curve by using the standard substance, and calculating the PreScision protease content in the detected sample according to the standard curve. According to the present invention, the antibody-antigen-antibody sandwich structure is formed through the double antibody sandwich, the SM17 is adopted as the capture antibody for coating, the SM10 is adopted as the detection antibody, the PreScision protease content is quantitatively detected through the obtained standard curve, and the sensitivity, the precision and the accuracy of the detection method provided by the present invention are maintained at the high level.

The application provides a set of methods for constructing antigen-antibody complex mutual recognition interface descriptors (i.e., protein molecular fingerprints), which maximally present the structure and physicochemical characteristics of specific recognition by describing the binding interface of the three-dimensional structure of the antibody-antigen from both sides. Based on the protein molecular fingerprints generated by the set of methods, based on the specific interaction recognition rules of the antigen-antibody, the epitope prediction algorithm specific to the antibody and the virtual screening model of the antibody are designed, and the existing machine learning or deep learning tools are docked, so that the antigen epitope prediction based on the antibody and the high-throughput virtual screening of the antibody based on the specific epitope can be quickly realized.

Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates) thereof that bind CD73 are disclosed. The disclosure further relates to methods and compositions for use in the treatment of, e.g., cancer by administering the compositions provided herein.

This provides methods and materials involved in binding a molecule (e.g., an antibody, a fragment of an antibody, an antibody domain, a chimeric antigen receptor (CAR), a cell engager, or an antibody-drug conjugate (ADC)) to a B7 homolog 3 (B7-H3) polypeptide (e.g., a human B7-H3 polypeptide). For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, or ADCs) that bind to a B7-H3 polypeptide as well as methods and materials for using such binders to treat cancer are provided. Also provided are cells (e.g., host cells) designed to express one or more binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, or cell engagers) having the ability to bind to a B7-H3 polypeptide as well as methods and materials for using such cells to treat cancer.

Delta-like ligand 3 (DLL3) binding molecules, particularly human antibodies, including antibody fragments, specific for DLL3 are provided. Also provided are recombinant receptors, including chimeric antigen receptors (CARs) comprising such antibodies or fragments, and polynucleotides encoding antibodies, antigen binding fragments or receptors specific for DLL3. Also provided are genetically engineered cells containing such DLL3 binding proteins and receptors, as well as related methods and uses thereof in adoptive cell therapy.

Disclosed herein are polyethylene glycol (PEG)-lipids, functionalized PEG-lipids, and functionalized PEG-lipids that are conjugated to a binding moiety which can comprise an antibody antigen binding domain. Also disclosed are methods for synthesizing and functionalizing the PEG-lipids. The PEG-lipids are useful components lipid nanoparticles (LNP) used for the delivery of nucleic acids into living cells, in vivo or ex vivo. LNP comprising functionalized PEG-lipids that are conjugated to a binding moiety are useful as targeted LNP for delivering nucleic acids into cells or tissues expressing the ligand of the binding moiety.

Provided herein are methods and materials relating to binding conjugates (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell cement, and / or ADCs) to BAFF-R polypeptides. For example, provided herein are conjugates (e.g., antibodies, antigen-binding fragments, antibody domains, CARs, cell cement, and / or ADCs) that bind to BAFF-R polypeptides, and methods and materials for using one or more such binding molecules to treat mammals (e.g., humans) having a cancer (e.g., one or more B-cell carcinoma).

An embodiment provides a method for treating a body fluid of a patient with an inflammatory cytokine storm, including: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with an antigen in the body fluid to form an antibody-antigen complex; removing the antibody-antigen complex from the body fluid; and returning the body fluid to the patient. Other aspects are described and claimed.

The invention discloses a chemiluminiscence detection reagent for detecting an HCV antibody and a use method of the chemiluminiscence detection reagent, and relates to the technical field of immunodetection. The detection reagent is combined with a sandwich method and an indirect method for detection. When in use, a sample is incubated with the first reagent and the sample treating fluid, so that the HCV antibody to be detected in the sample reacts with the HCV coating antigen in the first reagent to form an antigen-antibody compound; adding a second reagent, and reacting the formed antigen-antibody compound with the HCV labeled antigen labeled by acridinium ester and the anti-IgG antibody labeled by acridinium ester in the second reagent to form an antigen-antibody-antigen compound and an antigen-antibody-secondary antibody compound; and finally, adding excitation liquid to enable acridinium ester to emit light, and detecting the HCV antibody in the sample by detecting a light-emitting signal value. The technical scheme of the invention greatly improves the sensitivity and specificity of HCV antibody detection, and can be used for solving the problem of easy missing detection in HCV antibody detection.

This disclosure provides an anti-SIGLEC15 antibody, antigen-binding fragment, and the use thereof.

The present application belongs to the field of biosensing technology and tumor marker instant detection, and particularly relates to a preparation method of a human epididymis protein 4 (HE4) biosensor based on electrochemical principle and detection application thereof. The present application constructs an "antibody-antigen-antibody" sandwich complex structure, realizes simple, accurate and efficient detection of serum HE4; the KB-PEI@AuNPs composite material is used as a base material, which can effectively fix antibody molecules and promote electron transmission of the electrode interface, and significantly improves the conductive performance of the sensor; by using the specific binding principle of antigen and antibody, the CoFeZn-MOF prepared by the present application has peroxidase-like activity as a nanoenzyme; when the electrode modified by the probe CoFeZn-MOF / Ab2 is detected, the nanoenzyme can catalyze H2O2 to decompose to generate active oxygen substances such as hydroxyl radicals; this redox process triggers electron transfer, thereby causing a change in the current signal, thereby exhibiting i-t rapid response characteristics, high sensitivity performance and a lower detection limit.

The present invention includes antibodies and antigen-binding fragments thereof that specifically bind a double-stranded deoxyribonucleic acid (DNA) strand. Polynucleotides encoding an antibody or an antigen-binding fragment, vectors, and host cells that comprise a polynucleotide and pharmaceutical compositions are also included in this invention. Also described herein are methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to diagnose, prevent or treat a DNA virus infection.